We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Could the Hurricane Energy share price be the bargain of the year?

G A Chester weighs up the potential of exciting oil stock Hurricane Energy plc (LON:HUR) and a pharma firm aiming to rise like a phoenix.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

There’s no shortage of loss-making-but-high-potential companies on the stock market. Oil explorers and developers and pharmaceuticals and medical technology firms offer the prospect of particularly big gains for investors who identify the right company at the right price.

Of course, this is easier said than done. For every millionaire-maker there are dozens of duds. Today, I’m weighing up the potential of oil stock Hurricane Energy (LSE: HUR) and pharma player Circassia (LSE: CIR), which released its annual results today.

Should you buy Hurricane Energy Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Collapse

Heavily backed by cornerstone investors Neil Woodford and his protégé at former employer Invesco, Circassia pursued the development of a whole platform of allergy treatments that were said to build immunity quicker than existing remedies and without the risk of anaphylactic shocks. When its lead cat allergy failed a Phase III study, the entire programme collapsed.

At the height of investor confidence, Circassia was a member of the FTSE 250 index, with a share price of 350p and market capitalisation of over £1bn. Today, it’s on the AIM market, its share price is 31.5p (down a little on the back of its results) and its market cap is £118m. Its accounts show an accumulated loss of over half-a-billion quid.

However, it now has a small portfolio of revenue-generating products, including via a commercial collaboration with AstraZeneca, which has also become a 19% shareholder in Circassia. Could the stock be set to rise like a phoenix?

Recovery?

Just over a year ago, I wrote that I wouldn’t touch Circassia with a bargepole, noting also a 5.42% short position in the stock held by hedge fund Mangrove.

Today’s results showed a £37.2m operating loss on revenue of £48.3m. There are signs of promising revenue growth, and with the share price much lower than a year ago, the valuation picture has improved.

However, continued losses are forecast into next decade and Mangrove has maintained its chunky short position. I’m not convinced the risk/reward proposition with Circassia is compelling, and so continue to see it as a stock to avoid at this stage.

Share price to double?

By contrast, when I last wrote about Hurricane Energy (November 2017), I felt its progress to date, potential to become a major player in the West of Shetland region, and share price of 26.75p (market cap £524m) represented an attractive risk/reward proposition. The shares are currently trading at around 47p (market cap £921m), but I continue to see a compelling investment opportunity.

The company is on track to deliver first oil from its 100%-owned Lancaster discovery before the end of June. Planned initial production is 17,000 barrels a day, and management expects to generate over $200m in operating cash flow on a full-year run-rate basis at a $60 a barrel Brent oil price.

Meanwhile, a 50% farm-in to its Warwick and Lincoln fields by Spirit Energy, providing up to $387m, has enabled an acceleration of activity, including the drilling of three wells this year, one of which was spudded last month.

If we see the company successfully executing on this year’s work programme, I think the share price could easily double from its current level. And with total 2P reserves and 2C contingent resources across the asset base standing at 2.3bn barrels net to Hurricane, there’s potential for the value of the company to continue increasing as time goes on.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black couple enjoying shopping together in UK high street
Investing Articles

Ramsdens Holdings: a sub-£5 stock offering growth and passive income

This high-flying small-cap stock is paying investors ‘special’ dividends at the moment. Could it be worth considering for passive income?

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

Up 15%, B&M shares are leading the FTSE 250 higher! Is the comeback on?

It's been a tough few years for battered retailer B&M and its shares. But is the FTSE 250 stock now…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

Growth AND dividends? Check out this top cheap penny share!

Looking to get maximum bang for your buck? Consider this white-hot UK penny share with an 11.5% dividend yield and…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

Snowflake lit up my ISA last week. Could this AI stock be next?

Edward Sheldon’s ISA got a massive boost last week when Snowflake shares surged 40%. He believes there’s more to come…

Read more »

A senior man using hiking poles, on a hike on a coastal path along the coastline of Cornwall. He is looking away from the camera at the view.
Investing Articles

How much would you need in an ISA to match the new State Pension and get another £12,547 a year?

Harvey Jones says nobody should rely purely on the State Pension to fund retirement. They should also aim to generate…

Read more »

Rear view image depicting a senior man in his 70s sitting on a bench leading down to the iconic Seven Sisters cliffs on the coastline of East Sussex, UK. The man is wearing casual clothing - blue denim jeans, a red checked shirt, navy blue gilet. The man is having a rest from hiking and his hiking pole is leaning up against the bench.
Investing Articles

How much is £9,999 invested in a Cash ISA 9 years ago worth today?

Harvey Jones says the Cash ISA may look tempting but is likely to shrink the value of your money over…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Are Lloyds shares 23% undervalued?

Lloyds shares have fallen in value since a high reached earlier this year. Could this be a sign the FTSE…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Here’s why Legal & General is still one of the UK’s most popular SIPP buys

So far in 2026, UK SIPP investors have largely stuck to the same group of favourite FTSE 100 stocks. And…

Read more »